CA2364503A1

CA2364503A1 - Compositions and methods for treating cancer and hyperproliferative disorders

Compositions and methods for treating cancer and hyperproliferative disorders Download PDF

Info

Publication number: CA2364503A1
Authority: CA; Canada
Prior art keywords: growth factor; composition; peptide; mice; immunogenic peptide
Prior art date: 1999-03-11
Legal status : Abandoned

Application number

CA002364503A

Other languages

English (en)

French (fr)

Inventor

John W. Holaday

Antonio Ruiz

John Madsen

Stacy M. Plum

Current Assignee

Casi Pharmaceuticals Inc

Original Assignee

Individual

Priority date

1999-03-11

Filing date

2000-03-10

Publication date

2000-09-14

1999-03-11 Priority claimed from US09/266,543 external-priority patent/US6805865B1/en

2000-03-10 Application filed by Individual filed Critical Individual

2000-09-14 Publication of CA2364503A1 publication Critical patent/CA2364503A1/en

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 155
206010028980 Neoplasm Diseases 0.000 title claims abstract description 137
238000000034 method Methods 0.000 title claims abstract description 105
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 51
201000011510 cancer Diseases 0.000 title claims abstract description 45
230000003463 hyperproliferative effect Effects 0.000 title claims description 14
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 218
239000003102 growth factor Substances 0.000 claims abstract description 189
241001465754 Metazoa Species 0.000 claims abstract description 46
230000033115 angiogenesis Effects 0.000 claims abstract description 41
241000282414 Homo sapiens Species 0.000 claims abstract description 33
201000010099 disease Diseases 0.000 claims abstract description 33
230000028993 immune response Effects 0.000 claims abstract description 23
239000003937 drug carrier Substances 0.000 claims abstract description 16
239000002502 liposome Substances 0.000 claims description 148
230000002163 immunogen Effects 0.000 claims description 72
210000004027 cell Anatomy 0.000 claims description 67
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 61
229920000669 heparin Polymers 0.000 claims description 61
229960002897 heparin Drugs 0.000 claims description 61
150000001413 amino acids Chemical group 0.000 claims description 51
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 49
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 48
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 46
239000002671 adjuvant Substances 0.000 claims description 42
150000002632 lipids Chemical group 0.000 claims description 39
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 35
102000005962 receptors Human genes 0.000 claims description 34
108020003175 receptors Proteins 0.000 claims description 34
108010033276 Peptide Fragments Proteins 0.000 claims description 33
102000007079 Peptide Fragments Human genes 0.000 claims description 33
206010027476 Metastases Diseases 0.000 claims description 28
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 27
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 27
229940126864 fibroblast growth factor Drugs 0.000 claims description 22
230000002209 hydrophobic effect Effects 0.000 claims description 18
208000035475 disorder Diseases 0.000 claims description 17
206010029113 Neovascularisation Diseases 0.000 claims description 16
230000009401 metastasis Effects 0.000 claims description 15
108091003079 Bovine Serum Albumin Proteins 0.000 claims description 13
102000014914 Carrier Proteins Human genes 0.000 claims description 13
108010078791 Carrier Proteins Proteins 0.000 claims description 13
229920000642 polymer Polymers 0.000 claims description 13
206010012689 Diabetic retinopathy Diseases 0.000 claims description 12
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 10
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 9
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 8
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 8
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
150000008575 L-amino acids Chemical class 0.000 claims description 7
206010038933 Retinopathy of prematurity Diseases 0.000 claims description 7
229940098773 bovine serum albumin Drugs 0.000 claims description 7
201000011066 hemangioma Diseases 0.000 claims description 7
208000002780 macular degeneration Diseases 0.000 claims description 7
108010040721 Flagellin Proteins 0.000 claims description 6
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 6
108010058846 Ovalbumin Proteins 0.000 claims description 6
108010071390 Serum Albumin Proteins 0.000 claims description 6
102000007562 Serum Albumin Human genes 0.000 claims description 6
102000009843 Thyroglobulin Human genes 0.000 claims description 6
108010034949 Thyroglobulin Proteins 0.000 claims description 6
206010003246 arthritis Diseases 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
239000003995 emulsifying agent Substances 0.000 claims description 6
108010074605 gamma-Globulins Proteins 0.000 claims description 6
239000000499 gel Substances 0.000 claims description 6
229940092253 ovalbumin Drugs 0.000 claims description 6
239000003755 preservative agent Substances 0.000 claims description 6
239000003381 stabilizer Substances 0.000 claims description 6
229960002175 thyroglobulin Drugs 0.000 claims description 6
230000029663 wound healing Effects 0.000 claims description 6
208000010412 Glaucoma Diseases 0.000 claims description 5
235000021314 Palmitic acid Nutrition 0.000 claims description 5
201000004681 Psoriasis Diseases 0.000 claims description 5
239000002158 endotoxin Substances 0.000 claims description 5
229920006008 lipopolysaccharide Polymers 0.000 claims description 5
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 5
201000003142 neovascular glaucoma Diseases 0.000 claims description 5
230000004862 vasculogenesis Effects 0.000 claims description 5
241000894006 Bacteria Species 0.000 claims description 4
241000588832 Bordetella pertussis Species 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 4
206010017076 Fracture Diseases 0.000 claims description 4
208000002260 Keloid Diseases 0.000 claims description 4
229920000057 Mannan Polymers 0.000 claims description 4
208000008469 Peptic Ulcer Diseases 0.000 claims description 4
206010037649 Pyogenic granuloma Diseases 0.000 claims description 4
206010039710 Scleroderma Diseases 0.000 claims description 4
206010043189 Telangiectasia Diseases 0.000 claims description 4
FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 claims description 4
229940037003 alum Drugs 0.000 claims description 4
150000001450 anions Chemical class 0.000 claims description 4
208000021921 corneal disease Diseases 0.000 claims description 4
229960000633 dextran sulfate Drugs 0.000 claims description 4
230000011132 hemopoiesis Effects 0.000 claims description 4
210000001117 keloid Anatomy 0.000 claims description 4
208000032839 leukemia Diseases 0.000 claims description 4
230000005906 menstruation Effects 0.000 claims description 4
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 4
230000002107 myocardial effect Effects 0.000 claims description 4
230000016087 ovulation Effects 0.000 claims description 4
208000011906 peptic ulcer disease Diseases 0.000 claims description 4
230000028742 placenta development Effects 0.000 claims description 4
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 4
208000009056 telangiectasis Diseases 0.000 claims description 4
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
208000022211 Arteriovenous Malformations Diseases 0.000 claims description 3
208000003732 Cat-scratch disease Diseases 0.000 claims description 3
241000589989 Helicobacter Species 0.000 claims description 3
239000005639 Lauric acid Substances 0.000 claims description 3
239000005642 Oleic acid Substances 0.000 claims description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
235000021355 Stearic acid Nutrition 0.000 claims description 3
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
230000005744 arteriovenous malformation Effects 0.000 claims description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
229960004488 linolenic acid Drugs 0.000 claims description 3
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
235000021313 oleic acid Nutrition 0.000 claims description 3
239000008117 stearic acid Substances 0.000 claims description 3
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 3
150000008574 D-amino acids Chemical class 0.000 claims 5
108060003552 hemocyanin Proteins 0.000 claims 5
150000004668 long chain fatty acids Chemical class 0.000 claims 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract description 124
102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract description 117
239000012634 fragment Substances 0.000 abstract description 42
108090000623 proteins and genes Proteins 0.000 abstract description 35
102000004169 proteins and genes Human genes 0.000 abstract description 32
230000012010 growth Effects 0.000 abstract description 28
230000004663 cell proliferation Effects 0.000 abstract description 26
210000002889 endothelial cell Anatomy 0.000 abstract description 20
230000002401 inhibitory effect Effects 0.000 abstract description 16
230000004614 tumor growth Effects 0.000 abstract description 15
230000002159 abnormal effect Effects 0.000 abstract description 12
230000008569 process Effects 0.000 abstract description 9
230000001404 mediated effect Effects 0.000 abstract description 6
108010041308 Endothelial Growth Factors Proteins 0.000 abstract 1
241000699670 Mus sp. Species 0.000 description 141
102000004196 processed proteins & peptides Human genes 0.000 description 73
235000001014 amino acid Nutrition 0.000 description 42
229940024606 amino acid Drugs 0.000 description 41
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
229960005486 vaccine Drugs 0.000 description 35
210000002966 serum Anatomy 0.000 description 32
210000004072 lung Anatomy 0.000 description 31
235000018102 proteins Nutrition 0.000 description 29
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
238000002255 vaccination Methods 0.000 description 26
230000000694 effects Effects 0.000 description 23
230000035755 proliferation Effects 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
238000002474 experimental method Methods 0.000 description 18
238000011161 development Methods 0.000 description 16
230000002491 angiogenic effect Effects 0.000 description 15
230000000890 antigenic effect Effects 0.000 description 15
230000018109 developmental process Effects 0.000 description 15
238000005538 encapsulation Methods 0.000 description 15
230000009257 reactivity Effects 0.000 description 15
210000004881 tumor cell Anatomy 0.000 description 15
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 14
238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 14
238000004458 analytical method Methods 0.000 description 14
235000012000 cholesterol Nutrition 0.000 description 14
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 14
229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 14
BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 14
229910052757 nitrogen Inorganic materials 0.000 description 14
239000007924 injection Substances 0.000 description 13
238000002347 injection Methods 0.000 description 13
210000004185 liver Anatomy 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
241000701447 unidentified baculovirus Species 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 12
229960000583 acetic acid Drugs 0.000 description 12
229940107161 cholesterol Drugs 0.000 description 12
206010061289 metastatic neoplasm Diseases 0.000 description 12
210000004204 blood vessel Anatomy 0.000 description 11
239000008188 pellet Substances 0.000 description 11
150000003904 phospholipids Chemical class 0.000 description 11
239000000243 solution Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
108010010803 Gelatin Proteins 0.000 description 10
238000003556 assay Methods 0.000 description 10
230000001413 cellular effect Effects 0.000 description 10
238000009472 formulation Methods 0.000 description 10
239000008273 gelatin Substances 0.000 description 10
229920000159 gelatin Polymers 0.000 description 10
235000019322 gelatine Nutrition 0.000 description 10
235000011852 gelatine desserts Nutrition 0.000 description 10
230000003053 immunization Effects 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
238000002965 ELISA Methods 0.000 description 9
206010027458 Metastases to lung Diseases 0.000 description 9
230000002942 anti-growth Effects 0.000 description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
230000021615 conjugation Effects 0.000 description 9
238000002513 implantation Methods 0.000 description 9
230000008595 infiltration Effects 0.000 description 9
238000001764 infiltration Methods 0.000 description 9
238000011081 inoculation Methods 0.000 description 9
239000002904 solvent Substances 0.000 description 9
QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 8
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 8
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
241000700605 Viruses Species 0.000 description 8
210000003743 erythrocyte Anatomy 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
201000001441 melanoma Diseases 0.000 description 8
230000004044 response Effects 0.000 description 8
241000282412 Homo Species 0.000 description 7
241001529936 Murinae Species 0.000 description 7
238000007792 addition Methods 0.000 description 7
230000005875 antibody response Effects 0.000 description 7
239000000427 antigen Substances 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
230000006378 damage Effects 0.000 description 7
210000000987 immune system Anatomy 0.000 description 7
239000012528 membrane Substances 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
238000011282 treatment Methods 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
238000012286 ELISA Assay Methods 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000000969 carrier Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
230000009467 reduction Effects 0.000 description 6
238000011160 research Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
229930182816 L-glutamine Natural products 0.000 description 5
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
230000000735 allogeneic effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000011888 foil Substances 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
230000036571 hydration Effects 0.000 description 5
238000006703 hydration reaction Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
239000010410 layer Substances 0.000 description 5
210000000265 leukocyte Anatomy 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000001394 metastastic effect Effects 0.000 description 5
229920000747 poly(lactic acid) Polymers 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
208000011581 secondary neoplasm Diseases 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000008223 sterile water Substances 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
238000004809 thin layer chromatography Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
229910004373 HOAc Inorganic materials 0.000 description 4
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
108010025020 Nerve Growth Factor Proteins 0.000 description 4
102000015336 Nerve Growth Factor Human genes 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
239000002870 angiogenesis inducing agent Substances 0.000 description 4
238000010171 animal model Methods 0.000 description 4
210000002469 basement membrane Anatomy 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
238000001516 cell proliferation assay Methods 0.000 description 4
230000009260 cross reactivity Effects 0.000 description 4
239000010432 diamond Substances 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
239000012362 glacial acetic acid Substances 0.000 description 4
230000002440 hepatic effect Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
229940053128 nerve growth factor Drugs 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000001717 pathogenic effect Effects 0.000 description 4
108010091742 peptide F Proteins 0.000 description 4
RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
108010005636 polypeptide C Proteins 0.000 description 4
238000000746 purification Methods 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000005748 tumor development Effects 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
108010009583 Transforming Growth Factors Proteins 0.000 description 3
102000009618 Transforming Growth Factors Human genes 0.000 description 3
239000002253 acid Substances 0.000 description 3
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
230000036755 cellular response Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
238000010231 histologic analysis Methods 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
239000007943 implant Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
229940047122 interleukins Drugs 0.000 description 3
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
230000003902 lesion Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000017066 negative regulation of growth Effects 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
108010069653 peptide E (adrenal medulla) Proteins 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
241000894007 species Species 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
OVXIMRGEBNSORH-UHFFFAOYSA-N 2-[[2-[2-[[2-[[1-[1-[5-amino-2-[[2-amino-3-(1h-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylp Chemical compound CCC(C)C(C(O)=O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C1N(C(=O)C(CCC(N)=O)NC(=O)C(N)CC=2C3=CC=CC=C3NC=2)CCC1 OVXIMRGEBNSORH-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 2
101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
208000024556 Mendelian disease Diseases 0.000 description 2
241000204031 Mycoplasma Species 0.000 description 2
102400000058 Neuregulin-1 Human genes 0.000 description 2
108090000556 Neuregulin-1 Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
101800005149 Peptide B Proteins 0.000 description 2
241000255969 Pieris brassicae Species 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
108010057464 Prolactin Proteins 0.000 description 2
102100024819 Prolactin Human genes 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000012042 active reagent Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
-1 antibodies Proteins 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
230000005587 bubbling Effects 0.000 description 2
230000009702 cancer cell proliferation Effects 0.000 description 2
235000011089 carbon dioxide Nutrition 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
229940047120 colony stimulating factors Drugs 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
210000004246 corpus luteum Anatomy 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
208000001780 epistaxis Diseases 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
230000001497 fibrovascular Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
102000052502 human ELANE Human genes 0.000 description 2
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
230000009545 invasion Effects 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
208000037841 lung tumor Diseases 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
230000014399 negative regulation of angiogenesis Effects 0.000 description 2
230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
108010091748 peptide A Proteins 0.000 description 2
239000012071 phase Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
238000003825 pressing Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
229940097325 prolactin Drugs 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000009877 rendering Methods 0.000 description 2
229920002477 rna polymer Polymers 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
210000004116 schwann cell Anatomy 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
239000007921 spray Substances 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
208000006379 syphilis Diseases 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
XOYXESIZZFUVRD-UVSAJTFZSA-N (2s,3s,4r,5s,6s)-6-[(2r,3r,4r,5s,6r)-6-[(2r,3s,4r,5s,6r)-5-acetamido-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6s)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]ox Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C(O)=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-N 0.000 description 1
KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003226 Arteriovenous fistula Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010044583 Bartonella Infections Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000009043 Chemical Burns Diseases 0.000 description 1
241001227713 Chiron Species 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
208000005590 Choroidal Neovascularization Diseases 0.000 description 1
206010060823 Choroidal neovascularisation Diseases 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
206010011017 Corneal graft rejection Diseases 0.000 description 1
206010055665 Corneal neovascularisation Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000019878 Eales disease Diseases 0.000 description 1
241000725630 Ectromelia virus Species 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
101500025915 Homo sapiens Angiostatin Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000003815 Interleukin-11 Human genes 0.000 description 1
108090000177 Interleukin-11 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
102000000704 Interleukin-7 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
102000000585 Interleukin-9 Human genes 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
206010024612 Lipoma Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
206010025412 Macular dystrophy congenital Diseases 0.000 description 1
241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
241000702623 Minute virus of mice Species 0.000 description 1
208000024599 Mooren ulcer Diseases 0.000 description 1
241000701168 Murine adenovirus 1 Species 0.000 description 1
241000711466 Murine hepatitis virus Species 0.000 description 1
241000711941 Murine orthopneumovirus Species 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
206010062207 Mycobacterial infection Diseases 0.000 description 1
HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
102000002111 Neuropilin Human genes 0.000 description 1
108050009450 Neuropilin Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
241001111421 Pannus Species 0.000 description 1
208000004788 Pars Planitis Diseases 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
208000010362 Protozoan Infections Diseases 0.000 description 1
201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
206010056342 Pulmonary mass Diseases 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
206010038934 Retinopathy proliferative Diseases 0.000 description 1
101150054830 S100A6 gene Proteins 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
239000004830 Super Glue Substances 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000018656 Terrien marginal degeneration Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
208000010011 Vitamin A Deficiency Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000002679 ablation Methods 0.000 description 1
229960005327 acemannan Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
206010004145 bartonellosis Diseases 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000001775 bruch membrane Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
201000000159 corneal neovascularization Diseases 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000021953 cytokinesis Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000008570 general process Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000036732 histological change Effects 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000016507 interphase Effects 0.000 description 1
210000002977 intracellular fluid Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000035984 keratolysis Effects 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
108010051201 lipid I Proteins 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000004880 lymph fluid Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
230000000684 melanotic effect Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
208000027531 mycobacterial infectious disease Diseases 0.000 description 1
208000001491 myopia Diseases 0.000 description 1
230000004379 myopia Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000011164 ossification Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 1
238000010926 purge Methods 0.000 description 1
WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000004264 retinal detachment Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
210000003583 retinal pigment epithelium Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
201000006476 shipyard eye Diseases 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000012353 t test Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000012549 training Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000006459 vascular development Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000007332 vesicle formation Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1